<code id='67417B67F0'></code><style id='67417B67F0'></style>
    • <acronym id='67417B67F0'></acronym>
      <center id='67417B67F0'><center id='67417B67F0'><tfoot id='67417B67F0'></tfoot></center><abbr id='67417B67F0'><dir id='67417B67F0'><tfoot id='67417B67F0'></tfoot><noframes id='67417B67F0'>

    • <optgroup id='67417B67F0'><strike id='67417B67F0'><sup id='67417B67F0'></sup></strike><code id='67417B67F0'></code></optgroup>
        1. <b id='67417B67F0'><label id='67417B67F0'><select id='67417B67F0'><dt id='67417B67F0'><span id='67417B67F0'></span></dt></select></label></b><u id='67417B67F0'></u>
          <i id='67417B67F0'><strike id='67417B67F0'><tt id='67417B67F0'><pre id='67417B67F0'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:576
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In